Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.71
AMRN's Cash to Debt is ranked lower than
69% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. AMRN: 0.71 )
Ranked among companies with meaningful Cash to Debt only.
AMRN' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.71

Equity to Asset -0.29
AMRN's Equity to Asset is ranked lower than
99% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. AMRN: -0.29 )
Ranked among companies with meaningful Equity to Asset only.
AMRN' s 10-Year Equity to Asset Range
Min: -0.82   Max: 1
Current: -0.29

-0.82
1
F-Score: 4
Z-Score: -5.54
M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -164.67
AMRN's Operating margin (%) is ranked lower than
91% of the 647 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.81 vs. AMRN: -164.67 )
Ranked among companies with meaningful Operating margin (%) only.
AMRN' s 10-Year Operating margin (%) Range
Min: -6232.2   Max: -9.44
Current: -164.67

-6232.2
-9.44
Net-margin (%) -103.96
AMRN's Net-margin (%) is ranked lower than
90% of the 647 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.76 vs. AMRN: -103.96 )
Ranked among companies with meaningful Net-margin (%) only.
AMRN' s 10-Year Net-margin (%) Range
Min: -5384   Max: 16.15
Current: -103.96

-5384
16.15
ROA (%) -30.82
AMRN's ROA (%) is ranked lower than
87% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. AMRN: -30.82 )
Ranked among companies with meaningful ROA (%) only.
AMRN' s 10-Year ROA (%) Range
Min: -549.69   Max: 10.46
Current: -30.82

-549.69
10.46
ROC (Joel Greenblatt) (%) -11733.26
AMRN's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.39 vs. AMRN: -11733.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMRN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -41760.19   Max: -26.88
Current: -11733.26

-41760.19
-26.88
EBITDA Growth (3Y)(%) -23.30
AMRN's EBITDA Growth (3Y)(%) is ranked lower than
83% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. AMRN: -23.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AMRN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 85.5
Current: -23.3

0
85.5
EPS Growth (3Y)(%) -15.50
AMRN's EPS Growth (3Y)(%) is ranked lower than
72% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. AMRN: -15.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AMRN' s 10-Year EPS Growth (3Y)(%) Range
Min: -81.1   Max: 155.7
Current: -15.5

-81.1
155.7
» AMRN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AMRN Guru Trades in Q2 2014

Jim Simons 184,200 sh (New)
Steven Cohen 1,361,832 sh (unchged)
Pioneer Investments 270,000 sh (unchged)
» More
Q3 2014

AMRN Guru Trades in Q3 2014

Paul Tudor Jones 13,438 sh (New)
Steven Cohen Sold Out
Jim Simons Sold Out
» More
Q4 2014

AMRN Guru Trades in Q4 2014

Paul Tudor Jones 11,209 sh (-16.59%)
» More
Q1 2015

AMRN Guru Trades in Q1 2015

Jim Simons 732,490 sh (New)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 6.81
AMRN's P/S is ranked lower than
92% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. AMRN: 6.81 )
Ranked among companies with meaningful P/S only.
AMRN' s 10-Year P/S Range
Min: 3.45   Max: 3720
Current: 6.81

3.45
3720
Current Ratio 4.46
AMRN's Current Ratio is ranked higher than
74% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. AMRN: 4.46 )
Ranked among companies with meaningful Current Ratio only.
AMRN' s 10-Year Current Ratio Range
Min: 0.27   Max: 35.14
Current: 4.46

0.27
35.14
Quick Ratio 4.08
AMRN's Quick Ratio is ranked higher than
75% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. AMRN: 4.08 )
Ranked among companies with meaningful Quick Ratio only.
AMRN' s 10-Year Quick Ratio Range
Min: 0.22   Max: 35.14
Current: 4.08

0.22
35.14
Days Inventory 269.67
AMRN's Days Inventory is ranked lower than
91% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.86 vs. AMRN: 269.67 )
Ranked among companies with meaningful Days Inventory only.
AMRN' s 10-Year Days Inventory Range
Min: 54.08   Max: 650.68
Current: 269.67

54.08
650.68
Days Sales Outstanding 52.71
AMRN's Days Sales Outstanding is ranked higher than
66% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.43 vs. AMRN: 52.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRN' s 10-Year Days Sales Outstanding Range
Min: 20.72   Max: 1521.32
Current: 52.71

20.72
1521.32

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -18.60
AMRN's Earnings Yield (Greenblatt) is ranked lower than
90% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.00 vs. AMRN: -18.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
AMRN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -22.4   Max: 1906886
Current: -18.6

-22.4
1906886

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:EH3A.Germany,
Amarin Corp PLC formerly Ethical Holdings plc is a public limited company incorporated under the laws of England and Wales. It was originally incorporated in England as a private limited company on March 1, 1989 under the Companies Act 1985, and re-registered in England as a public limited company on March 19, 1993. The Company is a biopharmaceutical company having expertise in lipid science focused on the commercialization and development of therapeutics to improve cardiovascular health. The Company's product Vascepa (icosapent ethyl) capsules is approved by the U.S. Food and Drug Administration for the use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (TG>500mg/dL) hypertriglyceridemia. On January 28, 2013 the Company commenced full commercial launch of Vascepa. The Company refers to its second indication for Vascepa as the ANCHOR indication. The FDA views the proposed ANCHOR indication as ostensibly and impliedly an indication to reduce cardiovascular risk. In addition, in December 2011, the Company announced commencement of patient dosing in cardiovascular outcomes study of Vascepa, titled REDUCE-IT or Reduction of Cardiovascular Events with EPA—Intervention Trial. The REDUCE-IT study is designed to evaluate the efficacy of Vascepa in reducing cardiovascular events in a high risk patient population on statin therapy. The Company has over 6,500 patients enrolled in the REDUCE-IT study. The Company has pending supplemental new drug application, with the FDA that seeks marketing approval of Vascepa for use in the ANCHOR indication. Vascepa became commercially available in the United States by prescription in early 2013. On January 28, 2013, the Company commenced full commercial launch of Vascepa in the United States for use in the MARINE indication. The Company now markets Vascepa in the United States through sales force of approximately 150 sales professionals and also employed marketing and medical affairs personnel to support commercialization of Vascepa. As of February 1, 2014, over 16,000 clinicians had written prescriptions for Vascepa. In November 2010, the Company reported top-line data for the MARINE trial. Vascepa was well tolerated in the MARINE trial, with a safety profile comparable to placebo and there were no treatment-related serious adverse events observed. No significant changes in fasting blood glucose, hemoglobin A1C, vital signs, electrocardiograms, or liver or kidney function were observed with either Vascepa dose. The Company uses third party manufacturers and suppliers to manufacture clinical and commercial quantities of ethyl-EPA, which constitutes the only active pharmaceutical ingredient within Vascepa, to encapsulate, bottle and package Vascepa and to maintain inventory of Vascepa. The Company currently relies on Patheon for the encapsulation of Vascepa. The Companies competitors include GlaxoSmithKline plc and AbbVie, Inc., and Niaspan. The Company is subject to
» More Articles for AMRN

Headlines

Articles On GuruFocus.com
Morning Coffee: Widely Held International Guru Stocks Near 52-Week Lows May 23 2014 
Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN Jan 07 2013 
Steven Cohen Adds Amarin Corp. Awaiting Drug Approval, Buys Hyatt Hotels Mar 28 2012 
Soros Funds’ Great Britain Buys and Sells Apr 13 2011 

More From Other Websites
AMARIN CORP PLC\UK Files SEC form 8-K, Other Events May 29 2015
Amarin (AMRN) in Focus: Stock Surges 19% in Session - Tale of the Tape May 29 2015
What Biotechnology Stocks Will Be Next To Enjoy The Bull Market? May 29 2015
Amarin's Lawsuit Could Have Huge Benefits For Pharma Industry And Dire Consequences For Consumers May 28 2015
Amarin Granted Summary Judgment Motion in Suit Against FDA Seeking New Chemical Entity Market... May 28 2015
2:45 pm Amarin confirms that a federal district judge has granted its motion for summary judgment in... May 28 2015
Amarin Granted Summary Judgment Motion in Suit Against FDA Seeking New Chemical Entity Market... May 28 2015
U.S. court grants exclusivity for Amarin's Vascepa May 28 2015
Amarin to Present at the Jefferies 2015 Global Healthcare Conference May 26 2015
Amarin to Present at the Jefferies 2015 Global Healthcare Conference May 26 2015
Why Amarin Corporation (AMRN) Could Be Positioned for a Slump - Tale of the Tape May 18 2015
AMARIN CORP PLC\UK Financials May 15 2015
Secret Letter To Doctors Shows That The Amarin Lawsuit Is About Marketing, Not Free Speech May 08 2015
Q1 2015 Amarin Corporation PLC Earnings Release - Before Market Open May 08 2015
Amarin Reports First Quarter 2015 Financial Results and Provides Update on Operations May 08 2015
AMARIN CORP PLC\UK Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 08 2015
Amarin Reports First Quarter 2015 Financial Results and Provides Update on Operations May 08 2015
Drug Firms Challenge FDA Over Free Speech May 07 2015
Irish drugmaker sues FDA under First Amendment May 07 2015
Irish drugmaker sues FDA under First Amendment May 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK